Mereo BioPharma vs Scienture
MREO and SCNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MREO and SCNX compare
Mereo BioPharma is the larger company, worth 1.9 times as much as Scienture ($219M against $113M).
Scienture scores higher on the StockData Score (3 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MREO | SCNX |
|---|---|---|
| Size and price | ||
| Market cap | $219M | $113M |
| Share price | $0.275 | $2.76 |
| Change, 1 year | −84.6% | −82.8% |
| Change, 5 years | −85.6% | −99.8% |
| Beta (5Y) | 2.29 | 1.19 |
| Employees | 39 | 8 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 9.2× | 1.8× (better) |
| FCF yield | −10.1% | – |
| Growth | ||
| Revenue growth, 5Y average | – | −52.1% |
| Profitability | ||
| Return on equity | −76.6% | −53.5% (better) |
| Return on invested capital | – | −47.3% |
| Financial health | ||
| Interest coverage | −440.6× | −13.1× (better) |
| Current ratio | 5.22 (better) | 3.04 |
| Altman Z-score | −4.68 | 0.07 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 7.1% | – |
| Held by insiders | 0.18% | 16.6% |
| Short interest, % of float | – | 0.34% |
Go deeper
- MREO stock overview
- MREO income statement
- MREO valuation and score
- SCNX stock overview
- SCNX income statement
- SCNX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.